[192 Pages Report] The Next-Generation Breast Cancer Diagnostic & Screening Market size was estimated at USD 4.14 billion in 2023 and expected to reach USD 4.57 billion in 2024, at a CAGR 11.13% to reach USD 8.68 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Next-Generation Breast Cancer Diagnostic & Screening Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Next-Generation Breast Cancer Diagnostic & Screening Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Next-Generation Breast Cancer Diagnostic & Screening Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agendia Inc., Agilent Technologies, Inc., ARTIVION INC., Becton, Dickinson and Company, Benitec Biopharma Ltd, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Centogene N.V., Danaher Corporation, Epic Sciences, Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., Invivoscribe, Inc., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG, Pfizer Inc., QIAGEN N.V., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
This research report categorizes the Next-Generation Breast Cancer Diagnostic & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Product
- Accessories
- Breast Imaging Systems
- Software & Services
- Diagnostic Technology
- DNA Microarrays
- Lab-on-a-Chip & Reverse Transcriptase-PCR
- Molecular Diagnostics
- Next Generation Sequencing
- Protein Microarrays
- qPCR & Multiplexing
- Screening Technology
- Ionizing Breast Imaging Technologies
- 3D Breast Tomosynthesis
- Analog Mammography
- Cone-Beam Computed Tomography (CBCT)
- Contrast-Enhanced Mammography (CEM)
- Full-Field Digital Mammography (FFDM)
- Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI)
- Positron Emission Mammography (PEM)
- Positron Emission Tomography and Computed Tomography (PET-CT)
- Non-ionizing Breast Imaging Technologies
- Automated Whole-Breast Ultrasound (AWBU)
- Breast MRI
- Breast Thermography
- Breast Ultrasound
- Electric Impedance Tomography
- Optical Imaging
- Ionizing Breast Imaging Technologies
- Application
- Cancer Screening
- Companion Diagnostics
- Risk Analysis
- Therapeutic Monitoring
- End User
- Breast Care Centers
- Diagnostic Imaging Centers
- Hospitals & Clinics
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the Next-Generation Breast Cancer Diagnostic & Screening Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Next-Generation Breast Cancer Diagnostic & Screening Market?
- What are the technology trends and regulatory frameworks in the Next-Generation Breast Cancer Diagnostic & Screening Market?
- What is the market share of the leading vendors in the Next-Generation Breast Cancer Diagnostic & Screening Market?
- Which modes and strategic moves are suitable for entering the Next-Generation Breast Cancer Diagnostic & Screening Market?
US $
Euro €
GBP £
